Graft failure in the modern era of allogeneic hematopoietic SCT. (Q33404733)

26 July 2017

title

Graft failure in the modern era of allogeneic hematopoietic SCT. (English)

1 reference

26 July 2017

1

R Olsson

1 reference

26 July 2017

J Mattsson

6

0 references

author name string

M Remberger

2

1 reference

26 July 2017

M Schaffer

3

1 reference

26 July 2017

D M Berggren

4

1 reference

26 July 2017

B-M Svahn

5

1 reference

26 July 2017

O Ringden

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

10 December 2012

1 reference

Bone Marrow Transplantation

26 July 2017

published in

1 reference

26 July 2017

volume

48

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

537-543

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

26 July 2017

1 reference

Graft failure after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Peculiar immunobiology of bone marrow allografts. I. Graft rejection by irradiated responder mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

The role of busulfan in bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Anti-HLA antibodies in double umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Umbilical cord blood transplantation for children with thalassemia and sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

CONTACT-INDUCED CYTOTOXICITY BY LYMPHOID CELLS CONTAINING FOREIGN ISOANTIGENS

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Novel antibodies to the donor stem cell population CD34+/VEGFR-2+ are associated with rejection after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Developmental outcome in five children with Hurler syndrome after stem cell transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.239

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.239

1 reference

Dimensions Publication ID

26 July 2017

1027322816

0 references

1 reference